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Background: A germline, variant in the BRCA1 3’UTR (rs8176318) was previously shown to predict breast and
ovarian cancer risk in women from high-risk families, as well as increased risk of triple negative breast cancer. Here,
we tested the hypothesis that this variant predicts tumor biology, like other 3’UTR mutations in cancer.
Methods: The impact of the BRCA1-3’UTR-variant on BRCA1 gene expression, and altered response to external
stimuli was tested in vitro using a luciferase reporter assay. Gene expression was further tested in vivo by
immunoflourescence staining on breast tumor tissue, comparing triple negative patient samples with the variant
(TG or TT) or non-variant (GG) BRCA1 3’UTR. To determine the significance of the variant on clinically relevant
endpoints, a comprehensive collection of West-Irish breast cancer patients were tested for the variant. Finally, an
association of the variant with breast screening clinical phenotypes was evaluated using a cohort of women from
the High Risk Breast Program at the University of Vermont.
Results: Luciferase reporters with the BRCA1-3’UTR-variant (T allele) displayed significantly lower gene expression, as
well as altered response to external hormonal stimuli, compared to the non-variant 3’UTR (G allele) in breast cancer
cell lines. This was confirmed clinically by the finding of reduced BRCA1 gene expression in triple negative samples
from patients carrying the homozygous TT variant, compared to non-variant patients. The BRCA1-3’UTR-variant
(TG or TT) also associated with a modest increased risk for developing breast cancer in the West-Irish cohort
(OR = 1.4, 95% CI 1.1-1.8, p = 0.033). More importantly, patients with the BRCA1-3’UTR-variant had a 4-fold increased
risk of presenting with Stage IV disease (p = 0.018, OR = 3.37, 95% CI 1.3-11.0). Supporting that this finding is due to
tumor biology, and not difficulty screening, obese women with the BRCA1-3’UTR-variant had significantly less dense
breasts (p = 0.0398) in the Vermont cohort.
Conclusion: A variant in the 3’UTR of BRCA1 is functional, leading to decreased BRCA1 expression, modest
increased breast cancer risk, and most importantly, presentation with stage IV breast cancer, likely due to aggressive
tumor biology.
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Breast cancer is the third most common form of cancer,
with almost 1.5 million women in the world diagnosed
with the disease in 2010 alone [1,2]. The extensive use of
mammography has resulted in a large proportion of
breast cancer cases being detected at an earlier stage,
resulting in increased survival and outcome [3]. How-
ever, approximately 3-6% of patients continue to present
with metastatic disease at diagnosis throughout the US
and Europe [4,5]. As a significant number of cases present
with metastatic disease when the primary tumor is not lo-
cally advanced [6], one can hypothesize that there is het-
erogeneity in tumor biology between patients, versus a
failure of screening. Despite the presence of targeted thera-
peutics for hormone receptor sensitive and HER2 over-
expressing breast cancers, treatment of metastatic disease
remains incurable. Therefore, identification of women with
a predisposition to develop tumors that are more likely to
metastasize is critical to help develop improved prevention
and screening strategies for those individuals.
The Breast Cancer 1, early onset gene (BRCA1) located
on chromosome 17q21.31 [7,8] encodes a tumor suppres-
sor that plays a critical role in the DNA damage response
and repair pathways [9,10]. Germline variants in the open-
reading-frame of BRCA1 confer a mean risk of 54% and
39% for developing hereditary breast and ovarian cancer
(respectively) by age 70 [11-14]. However, BRCA1 open-
reading-frame variants only account for a small portion of
hereditary breast cancer cases that occur primarily in
young, premenopausal patients [15]. Therefore, the search
for additional germline variants, outside of the BRCA1
open-reading-frame predicting increased breast cancer
risk has been undertaken. Such variants in the BRCA1
3’UTR have recently been identified and were first im-
plicated in breast and ovarian cancer susceptibility in
high-risk families [16]. Two variants 5711 + 421 T/T and
5711 + 1286 T/T (located in the BRCA1 3’UTR) are as-
sociated with cancer risk in Thai women from breast
and ovarian cancer families (OR = 3.0). Independent
evaluation of the 5711 + 421 T/T variant (referred to
here as rs8176318 or the BRCA1-3’UTR-variant) revealed
significant variation in baseline frequency by ethnicity,
with a documented minor allele frequency in Irish popula-
tions of approximately 0.28 [17]. Homozygous G > T vari-
ants were found to be associated with increased risk of
breast cancer in African American women (OR = 9.48,
95% CI 1.01-88.80), and were specifically associated with
the development of triple negative breast cancer (OR =
12.19, 95% CI 1.29-115.21) [17]. This data suggests that
the BRCA1-3’UTR-variant not only confers an increased
risk of developing breast cancer, but may also be associ-
ated with tumor biology, since the propensity to develop
triple negative breast cancer is higher than that of the
other subtypes. One could hypothesize from these findingsthat the BRCA1-3’UTR-variant functions similarly to
that of canonical BRCA1 open-reading-frame variants,
which are more commonly associated with development
of triple negative breast cancer as opposed to the other
subtypes [18-20].
Open reading frame variants in BRCA1 have not clearly
been associated with unique tumor biology, but only have
been predictive of response to therapeutic agents that take
advantage of their inherent DNA repair defects [21]. In
contrast, 3’UTR variants in cancer- associated genes have
been shown to predict both altered response to specific
therapies, as well as inherent differences in tumor biology.
This is likely due to the fact that these variants are in re-
gions of regulatory elements that control the nature and
timing of gene expression, and their effects are only mani-
fest under particular extracellular and/or intracellular stim-
uli (for review see ([22]). One mechanism for regulation of
these variants is by trans-acting factors such as miRNAs,
which are rapidly altered by external factors such as geno-
toxic stress [23] and estrogen receptor signaling [24].
Based on evidence of the biological function of other
3’UTR variants in cancer, and the association of the
BRCA1-3’UTR-variant with breast cancer risk in two pre-
vious studies [16,17], we sought to investigate the impact
of this variant on BRCA1 expression and its association
with tumor biology as seen in clinical presentation in a
clinically well-annotated breast cancer population.
Methods
Luciferase reporter assay
Luciferase reporters containing either the rs8176318
G-allele or T-allele were generated by PCR amplification
of the BRCA1 3’UTR loci from HMEC genomic DNA
(heterozygous for the BRCA1-3’UTR-variant) using the
following DNA oligonucleotides:
BRCA1 forward 5’ ATGACTCGAGCTGCAGCCAGC
CACAGGTACAGAGCCACAG 3’
BRCA1 reverse 5’ ATGAGCGGCCGCGTGTTTGCT
ACCAAGTTTATTTGCAGTG 3’
PCR amplicons were subcloned into the XhoI and NotI
sites (underlined) of the psiCHECK2 dual luciferase vector
(Progema). Constructs were sequence verified to confirm
that the only difference in the BRCA1 3’UTR was the
rs8176318 variant.
MCF-7, MDA-MB-231, MDA-MB-361, MDA-MB-468,
Hs 578 T and BT-20 cells were purchased from the ATCC
and grown at 37°C and 5% CO2 according to the manufac-
turer’s protocol. MCF-7 and BT-20 cells were cultured
using MEM (GIBCO) supplemented with 10% fetal bo-
vine serum (GIBCO) and 100 ug/ml penicillin, 100 U
streptomycin. MDA-MB-231, MDA-MB-361 and MDA-
MB-468 cells were cultured using Leibovitz’s L-15 (GIBCO)
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penicillin, 100 U streptomycin. Hs5788T cells were cultured
in DMEM (GIBCO) supplemented with 10% fetal bovine
serum and 100 ug/ml penicillin, 100 U streptomycin.
Cells in log-growth phase were transfected with either
the G-allele or T-allele expressing luciferase reporters
(100 ng) using Lipfectamine 2000 (Invitrogen) according
to the manufacturer’s protocol. Following a 16-hour incu-
bation the cells were lysed and analyzed for dual luciferase
activities by quantitative titration using the dual luciferase
assay kit (Promega). Renilla luciferase was normalized to
firefly luciferase. Graphed is the mean ± standard devi-
ation (SD) of 3 independent experiments. Statistical sig-
nificance was determined by student’s t-test (1-tailed,
paired t-test). A p-value of less than 0.05 was considered
statistically significant.
Immunofluorescence staining of BRCA1 in tumor tissue
BRCA1 protein expression was analyzed from tumor tis-
sue derived from the triple negative breast cancer cohort
subset with corresponding BRCA1-3’UTR-variant geno-
type information, using an immunofluorescent platform,
AQUA™, on tissue microarrays (TMAs) of tumor cores.
BRCA1 protein was assessed using monoclonal MS110
Ab-1 anti-BRCA1 (Calbiochem) [25-27] and rabbit poly-
clonal anticytokeratin (DAKO), at dilutions of 1:100 and
1:200 respectively in 0.3% BSA/TBS buffer for 1 h at 37°C.
AQUA has been described previously [28,29].
Estrogen withdrawal assay
MCF-7 cells cultured in phenol-red free MEM (GIBCO)
containing 5% fetal bovine serum and 100 ug/ml penicil-
lin, 100 U streptomycin, were treated with either 100 nM
Fuvestrant (Sigma I4409) or β-Estradiol (Sigma E8875).
Following a 48-hour incubation, the cells were transfected
with luciferase reporters (100 ng) harboring either the
BRCA1 G-allele or T-allele 3’UTR using Lipofectamine
2000. After a 16-hour incubation the cells were lysed and
analyzed for dual luciferase activities by quantitative titra-
tion. Renilla luciferase was normalized to firefly luciferase.
Graphed is the mean ± SD of 3 independent experiments,
preformed in triplicate. Statistical significance was deter-
mined by student’s t-test (1-tailed, paired t-test). A p-value
of less than 0.05 was considered statistically significant.
Total RNA was isolated from cell lysates by Trizol ex-
traction as previously described [30]. cDNA was generated
using iScript cDNA Synthesis Kit (Bio-Rad). Target mRNA
was amplified by qPCR using iTaq SYBR Green Supermix
with ROX (Bio-Rad) on a 7900HT Fast Real-Time PCR
System (Applied Biosystems) using the following DNA
oligonucleotide primers:
Actin forward 5’ AGAAAATCTGGCACCACACC 3’
Actin reverse 5’ AGAGGCGTACAGGGATAGCA 3’GREB1 forward 5’ GTGGTAGCCGAGTGGACAAT 3’
GREB1 reverse 5’ TGTGCATTACGGACCAGGTA 3’
TFF1 forward 5’ CACCATGGAGAACAAGGTGA 3’
TFF1 reverse 5’ CCGAGCTCTGGGACTAATCA 3’
mRNA levels were calculated by the delta-delta CT
method [31]. Samples were run in triplicate and standard
deviation (SD) is the average of 3 independent experiments.
Study populations
All women with a biopsy confirming breast cancer at
Galway Hospital and its affiliates are approached to en-
roll in the breast cancer study including DNA collection.
Informed consent, a detailed family history of breast and/
or ovarian cancer and a peripheral venous blood sample
are obtained from cases and controls. Controls were
women from the west of Ireland, primarily over 60 years
of age, without a personal history of cancer of any type
and without a first-degree family member with breast or
ovarian cancer. These controls were accrued primarily
from Active Retirement association meetings and from
Nursing home residents. All cases and controls were re-
cruited following appropriate ethical approval from the
Galway University Ethics Committee. 728 cases and 387
controls were included from this cohort.
The Irish patient cohort consisted of 728 women with
invasive, primary operable breast cancer diagnosed be-
tween June 1980 and August 2007, with complete receptor
status (outlined in Additional file 1). Receptor status was
determined using established histopathological methods
and immunohistochemistry, followed by fluorescence in-
situ hybridisation (FISH) to confirm HER2/neu positivity
in samples that scored a 2+ on Hercept test. The samples
were then grouped into Luminal A, Luminal B, HER2 and
triple negative subtypes based on receptor status but in
the absence of gene expression analysis. Patient demo-
graphics and tumor characteristics were recorded and out-
come/survival data was prospectively maintained using
hospital medical records. Disease free survival (DFS) was
defined as time in months, from breast cancer diagnosis
to point of loco/regional recurrence or distant disease pro-
gression, progression free survival (PFS) was defined as
time in months from the point of diagnosis of Stage IV
cancer to disease progression and overall survival (OS)
was defined as the time from breast cancer diagnosis to
the end of follow-up or death (months).
The CT Triple Negative Breast Cancer (TNBC) Cohort
has been previously described [32], but briefly, FFPE tissue
was obtained from 134 TNBC patients, who underwent
surgery at the Yale University New Haven Hospital or the
Hospital of Bridgeport, Connecticut, between 1985 and
2007. Patient sample collection was performed through a
Yale HIC approved tissue collection protocol. Tissue of
120 patients was used for TMA construction and the
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and 19 years with a mean follow up of 4.4 years. Patient
age at diagnosis ranged from 30 to 90 years, with a mean
age at diagnosis of 53 years. Sixty-two patients were diag-
nosed as node negative and 40 patients as node positive.
There were 65 patients who were Caucasian in this cohort
who were used for this analysis. Treatment was known in
86% of patients, out of those 63% received chemotherapy.
Gene expression in TMAs was analyzed by AQUA tech-
nology [28,29], and results were reviewed and confirmed
by two independent pathologists.
The High Risk Breast Program from Vermont is a
database that is IRB approved and was established at the
University of Vermont in 2003. Eligible women include
those with a strong family history of breast cancer (55.2%
of participants), a prior breast biopsy showing atypical
ductal hyperplasia or lobular neoplasia (14.7%), a known
germline abnormality of BRCA1 or 2 (7.3%, but excluded
from this study), or a prior history of receiving chemo-
radiotherapy for Hodgkin’s disease (1.3%). At study entry,
unaffected high-risk women provide anthropometric mea-
surements, medical/family history, physical activity and
diet information, mammography reports, health behavior
information and provide a blood sample for storage that
may be used for future research. 536 women have been
enrolled into this database since 2003 with follow-up
visits, questionnaire completion and blood draws occur-
ring at 4 and 8 years after study entry. Status of enrolled
women (i.e., new cancer diagnosis) is updated on an on-
going annual basis. For this study, 367 women were geno-
typed for the BRCA1-variant.
BRCA1-3’UTR-variant genotyping
1–3 mL of whole blood was drawn from the Irish cases
and controls and DNA was isolated. DNA was isolated
from FFPE tissue for genotyping for the TNBC Cohort.
DNA was supplied from the Vermont cohort. From blood,
DNA was isolated using a DNA extraction kit (Gentra
Puregene) or Ambion according to the manufacturer’s
protocol. Genotyping was performed using a custom Taq-
Man genotyping assay (Applied Biosysytems) that was spe-
cific for rs8176318. Each reaction was performed in a 20 μl
volume using 10 μl of 2× TaqMan Genotyping MaterMix,
1 μl of the 20× variant assay, approximately 40 ng of DNA
and nuclease free water in a 96-well plate. The reactions
were run on the Applied Biosystems 7900HT Fast Real-
Time PCR System in a two-stage process incorporating
PCR amplification and allelic discrimination. Genotypes
were analyzed using the Applied Biosystems SDS 2.3 geno-
typing software and automatic calls were verified by ob-
serving the spectral contributions of the dye corresponding
to the sequence specific probe on the Multicomponent
Data Plot. Internal quality control was maintained using
established positive and negative controls to ensuregenotyping accuracy and 6% percent of DNA samples were
genotyped in duplicate with 100% consistency of results.
Two DNA samples of the 728 cases failed to amplify and
were excluded from further analyses. All Caucasian cases
from the TNBC cohort amplified and were included in the
analysis. All BRCA coding sequence non-mutant patients
from the Vermont cohort were included.
Statistical analysis
The genetic distribution of the breast cases and controls
were tested for Hardy-Weinberg equilibrium and were
found to be in equilibrium. In order to evaluate the distri-
bution of patient demographics in cases and controls as
well as tumor features among the cases, categorical vari-
ables were analyzed using the χ2 test and continuous vari-
ables were analyzed using t-tests. Binary logistic regression
was used to evaluate the association of each genotype with
cancer. Case–control analysis comparing genotypes in dif-
ferent models was performed using a χ2 test to obtain odds
ratios (OR), 95% Confidence Interval (CI) and p-values.
Based on the preceding statistical findings, the dominant
model was used for all further analyses.
Prevalence of the variant across cancer subtypes, and
comparison of the respective subtypes against controls
were evaluated using χ2 analyses. The Luminal A cases
were stratified according to menopausal status and the
observed genotype distribution compared with controls
using χ2 test. Association of the variant with ER/PR sta-
tus controlling for other patient and tumor variables was
analyzed using binary logistic regression.
Binary logistic regression was used to evaluate the inde-
pendent effect of metastasis and disease stage in predicting
variant positivity in all cancer cases and Luminal A cases
specifically. Logistic regression analyses for all cases and
Luminal A cases with a binary outcome variable coded as
rs8176318 positive (TT or GT genotypes) or negative (GG
genotype) included variables such as age at diagnosis,
menopausal status, tumor grade, ER/PR status and stage.
Cox Proportional Hazards models were fitted to evalu-
ate the effect of the variant on disease free survival, pro-
gression free survival and overall survival in all cancer
cases and according cancer stage.
Fisher’s Exact Test was used to examine the statistical
significance of the association between mammographic
density and the presence or absence of the BRCA1-
3’UTR-variant in both the entire population, as well as
in a variety of subsets (BMI categories, pre- or post-
menopausal women, and age at menarche categories).
Results
The BRCA1-3’UTR-variant is associated with decreased
gene expression in triple negative breast cancer cell lines
To evaluate if the BRCA1-3’UTR-variant alters BRCA1
gene expression, we generated and tested luciferase
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(G) BRCA1 3’UTR. Reporters were transfected into vari-
ous breast cancer cell lines and assayed for differences in
luciferase gene expression as a surrogate for BRCA1 ex-
pression in the presence or absence of the BRCA1-3’UTR-
variant. We found that the reporter with the T-allele had
decreased luciferase expression by approximately 1.4, 1.5
and 1.8-fold in BT-20, Hs 578 T and MDA-MB-468 triple
negative breast cancer cell lines, respectively (Figure 1).
We found no significant difference in luciferase expression
between the wild-type (G) and mutant (T) alleles in the
MDA-MB-361, the MDA-MB-231 or MCF-7 breast can-
cer cells.The BRCA1-3’UTR-variant is associated with decreased
BRCA1 gene expression in triple negative breast cancer
patients
To confirm our in vitro findings, we evaluated BRCA1
protein expression using our CT cohort of triple negative
breast cancer patient tumor samples, where BRCA1 pro-
tein staining and the BRCA1-3’UTR-variant genotype
analysis was available. While protein coding sequence
BRCA1 and BRCA2 variant status was unavailable for
these patients, based on previous work, the BRCA1
3’UTR variant is rarely found in patients with coding se-
quence variants [17]. Even without excluding protein
coding sequence mutants, we found BRCA1 expression
was significantly lower in TNBC tumor cores from pa-
tients harboring the BRCA1-3’UTR-variant (TT) alleles
compared to patients harboring hetero and homozygous
wild-type (TG and GG) alleles (Figure 2). These findings
support the hypothesis that the BRCA1-3’UTR-variant isFigure 1 The impact of the BRCA1-3’UTR-variant on luciferase express
either the non-variant (G-allele, dark grey) or variant (T-allele, light grey) BR
lines (as indicated). Following a 16-hour incubation the cells were lysed an
to firefly luciferase. T-allele expression was calculated relative to that of the
experiments. *p < 0.05; error bars represent the mean ± standard deviation.associated with lower BRCA1 protein expression in TNBC
tumors, as was seen in vitro.Estrogen withdrawal leads to altered gene expression
from the BRCA1-3’UTR-variant mutant allele
Based on our findings suggesting that at baseline the
BRCA1-3’UTR-variant led to differential BRCA expres-
sion, we next tested the hypothesis that the BRCA1-
3’UTR-variant T-allele could be differentially regulated
by external cellular events. We chose to study the im-
pact of the presence or absence of estrogen, based on its
association with altered expression in TNBC cell lines
and tumors. We therefore measured the impact of estro-
gen withdrawal on our mutant and wild-type luciferase
reporters. MCF-7 cells cultured in fulvestrant (an anti-
estrogen) or estrogen for 48-hours were transfected with
luciferase reporters harboring either the wild-type (G) or
mutant (T) BRCA1 3’UTR.
We found that estrogen withdrawal resulted in a sig-
nificant decrease in the expression of the mutant allele,
without any impact on the wild-type G-allele, indicating
that estrogen withdrawal differentially impacts the ex-
pression of the T-allele, leading to down-regulation of
luciferase expression in the absence of estrogen. In con-
trast, we found that the addition of estrogen had no ef-
fect on either the non-mutant (G-allele) or mutant
allele (T-allele) (Figure 3A). Estrogen depletion was con-
firmed by RT-PCR analysis of previously described es-
trogen responsive genes GREB1 [33] and TFF1 [34],
which displayed a 10-fold and 7-fold decrease in mRNA
expression (respectively) in cells treated with fulvestrant
(Figure 3B).ion in breast cancer cell lines. Dual luciferase reporters harboring
CA1 3’UTR were transiently transfected into various breast cancer cell
d luciferase activities were analyzed. Renilla luciferase was normalized
G-allele. Plotted is the mean and standard deviation of 4 independent
Figure 2 The BRCA1-3’UTR-variant and BRCA1 protein staining in CT TNBC patient tumor cores. Comparison of the degree of BRCA1
protein staining in a TMA according to respective alleles. A lower level of BRCA1 staining was noted in the homozygous mutant specimens (TT).
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cancer risk
To determine if there were clinical and biological im-
pacts of the BRCA1-3’UTR-variant, we studied a genetic-
ally and environmentally homogeneous population, to
best control for “context” effects on variant function. We
used our case–control analysis of 726 cases and 387 con-
trols from west-Ireland. Clinico-pathological variables of
breast cancer cases evaluated in this study and their asso-
ciation with the variant are in Additional file 1. Overall,
there was a significant difference in the distribution of the
three genotypes across cases and controls (p = 0.033), with
a higher proportion of cases displaying the mutant TT and
GT genotypes (60[8%] and 318[44%] of 726 cases respect-
ively) compared to controls (29[7%] and 141[36%] of 387
controls respectively). The dominant model was predictive
of breast cancer risk compared to controls for all breast
cancer patients (OR 1.4, 95% CI 1.1-1.8).
We next evaluated the association of the BRCA1-
3’UTR-variant across the various breast cancer subtypes.
Our cohort was comprised of 519 women with Luminal
A breast cancer, 84 with Luminal B disease, 40 with HER2
positive disease and 83 with triple negative breast cancer.
378 (52%) of the 726 breast cancer cases had the variant,
with similar prevalence between the subtypes (p = 0.392):
Luminal A (279 [54%] of 519 cases), Luminal B (37 [44%]
of 84 cases), HER2 (21 [53%] of 40 cases) and triple nega-
tive breast cancer (41 [49%] of 83 cases). Comparing theprevalence of the BRCA1-3’UTR-variant within respective
subtypes with controls, Luminal A breast cancer was most
strongly associated with the variant by the dominant
model (OR = 1.5, 95% CI 1.1-1.9). This association was
not seen with the other subtypes (Additional file 2), but
this was likely due to sample size.
Previous work indicated that the homozygous (TT)
mutant genotype was associated with triple negative
breast cancer in African American patients [17]. There-
fore, we evaluated the association of patient/tumor fea-
tures (age, menopausal status, stage, ER/PR status, and
tumor grade) with the homozygous TT variant compared
to hetero TG or homozygous GG alleles in all Irish cases.
In agreement with this prior study, Irish Caucasian pa-
tients with ER/PR negative disease were 2.2 times more
likely to carry the homozygous (TT) rs8176318 variant,
which was of borderline significance (95% CI 0.98-4.87,
p = 0.056).
The association of the BRCA1-3’UTR-variant with tumor
biology and clinical presentation
We next tested the hypothesis that the BRCA1-3’UTR-
variant may predict altered breast cancer biology in our
Irish cohort of patients. We found that both disease
stage (p = 0.015) and presence of distant metastasis at
presentation (p = 0.037) were significant predictors of the
BRCA1-3’UTR-variant. Regression analyses of all breast
cancer cases evaluating the contributory role of age,
Figure 3 Expression of the BRCA1-3’UTR-variant mutant allele with estrogen withdrawal. A. MCF-7 cells treated with either 100 nM
fulvestrant or estrogen for 48-hours, were transfected with dual luciferase reporter plasmids harboring either the non-variant (G-allele, dark grey)
or variant (T-allele, light grey) BRCA1 3’UTR. After a 16-hour incubation dual luciferase activities were measured. Renilla luciferase was normalized
to firefly luciferase. T-allele expression was calculated to that of the G-allele. Plotted is the mean and standard deviation of at 3 independent
experiments. *p < 0.05; error bars represent the mean ± standard deviation. B. Total RNA was isolated from cell lysates (A) by Trizol extraction.
RT-qPCR was utilized to access the effects of fulvestrant and estrogen treatment on mRNA expression of estrogen responsive markers (GREB1 and
TFF1). The results were normalized to β-Actin mRNA expression. *p < 0.05; error bars represent the mean ± standard deviation.
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in predicting the BRCA1-3’UTR-variant was significant
only for stage (Table 1). Moreover, patients with meta-
static disease (n = 23) at presentation had a four-fold risk
of carrying the BRCA1-3’UTR-variant compared to Stage
I breast cancer patients (p = 0.018, OR 3.73, 95% CI 1.26-
11.07). Put differently, 17 (73%) of the 23 patients with
metastatic disease at presentation were positive for the
BRCA1-3’UTR-variant, compared to 349 (51%) of 680
patients without metastatic lesions (p = 0.040, OR 2.7,
95% CI 1.1-6.9) (Table 2). Controlling for other diseasevariables in a multi-variant model, patients with Stage
IV disease were three-fold more likely to have the BRCA1-
3’UTR-variant compared to all other stages of breast can-
cer (p = 0.055, OR 2.76, 95% CI 1.0-7.8).
We further performed regression analysis of Luminal
A cases alone, evaluating the effect of patient age, meno-
pausal status, disease stage, tumor stage and grade on
the BRCA1-3’UTR-variant status. Again we found that the
BRCA1-3’UTR-variant was significant for disease stage.
Patients presenting with Stage IV disease with Luminal A
breast cancer had a 10-fold increased risk of carrying the
Table 1 Multivariate analysis evaluating the role of patient
and pathological factors on the BRCA1-3’UTR-variant
positivity
Multivariate analysis p-value OR 95% CI
Age 0.915 1 0.98-1.02
Menopausal status: Post 0.492 1.29 0.62-2.69
Grade 2 0.493 0.83 0.49-1.41
3 0.145 0.66 0.38-1.16
Stage 2 0.065 1.48 0.98-2.24
3 0.169 1.41 0.87-2.29
4 0.018 3.73 1.26-11.07
ER and/or PR status: Positive 0.603 0.88 0.56-1.41









Full cohort 93 70 0.2948
Pre-menopausal 49 39 0.7842
Post-menopausal 35 28 0.2530
Normal BMI 26 22 0.7342
Overweight BMI 29 20 0.3115
Obese BMI 36 26 0.0398
Menarche age 7-11 16 17 0.7848
Menarche age 12-13 48 33 0.4672
Menarche age ≥14 18 9 0.2123
*P-values represent significance of the association between mammographic
density and the presence or absence of rs8176318.
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0.033, OR 10.05, 95% CI 1.21-83.52). Presence of distant
metastasis at presentation was independently associated
with variant positivity, as 11 (92%) of 12 Luminal A pa-
tients with metastasis had the variant compared to 261
(53%) of 495 patients without metastasis (p = 0.029, OR
9.9, 95% CI 1.3-77.0) (Table 2). Controlling for other con-
founding pathological factors in a multivariant model,
Stage IV disease in Luminal A cases was again associated
with the BRCA1-3’UTR-variant compared to all other
stages (p = 0.053, OR 7.78, 95% CI 1.0-62.3). In contrast,
we found no difference between disease free survival, pro-
gression free or overall survival using either a recessive or
dominant model (data not shown).
The BRCA1-3’UTR-variant is not associated with features
predicting difficulty in detection
As mammographic screening is initiated at the age of 50
in Ireland, and all women standardly participate, we
tested the hypothesis that this mutation might predict
difficulty successfully detecting breast cancer using stand-
ard screening in these patients, explaining the association
with Stage IV presentation. We therefore studied a cohort
of women at high risk for breast cancer, with detailed in-
formation collected prospectively on health, screening and
outcomes from Vermont. Out of this cohort of 369 tested
women, 199 had the BRCA1 3’UTR variant. As dense
breast tissue predicts increased difficulty in tumor detec-
tion [35-37], we examined features of mammographicTable 2 Genotype distribution across metastasis status
All cases M1 M0 p-value OR (95% CI)
TT and GT 17 349 0.040 2.69 (1.05-6.90)
GG 6 331
Luminal A cases
TT and GT 11 261 0.029 9.86 (1.26-77.01)
GG 1 234density in this population. We found that women with the
BRCA1 3’UTR variant were actually significantly less likely
to have dense breast tissue compared to non-BRCA1
3’UTR mutant patients, when they had an obese BMI
(p = 0.0398) (Table 3). To better understand this, we an-
alyzed the relationship between each density category
and the BRCA1 3’UTR variant. We found that women
with the BRCA1 3’UTR variant were less likely to have
mammograms with scattered fibroglandular density (p =
0.1397) (Table 4 and Additional file 3), which contributes
to density. These findings suggest that mammographic
screening for women with this variant should be at least
as successful in detecting disease as in women without
this variant, and thus failed screening is not the explan-
ation for presentation with Stage IV disease.
Discussion
Here we show for the first time that the rs8176318 G > T
3’UTR variant (the BRCA1-3’UTR-variant) is associated
with decreased BRCA1 expression both in vitro and
in vivo, and is impacted by cellular exposure to estrogen.
More importantly, we show that this variant predicts ag-
gressive breast cancer biology and stage IV disease, as
well as modest increased breast cancer risk in a homo-
geneous well-characterized west-Irish population. In
addition, studying a collection of women at high risk for









Extremely dense 17 18 0.5936
Heterogeneously dense 89 82 0.5306
Scattered fibroglandular 66 44 0.1397
Fatty replaced 27 26 0.6576
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of mammograms to detect disease (lower mammo-
graphic density). These findings suggest that presenta-
tion with stage IV disease of BRCA1-3’UTR-variant
patients is unlikely to be due to the inability to detect
disease early, but instead suggests that this variant pre-
dicts biologically aggressive disease. These are hypoth-
esis deserving further investigation.
While the findings of increased cancer risk are in
agreement with prior reports [16,17], this is the first
study evaluating biologic function and clinical associa-
tions of the BRCA1-3’UTR-variant with the patients that
are carriers and develop cancer. While the search for
germ-line variants in BRCA1 have predominantly focused
on open-reading-frame variants, increasing evidence is
showing that alterations in non-coding regions of genes
(such as this variant) explain a proportion of cancer sus-
ceptibility, and more importantly play a role in tumor
biology and can act as prognostic biomarkers. While the
exact biological mechanism leading to altered BRCA1 ex-
pression in BRCA1-3’UTR-variant associated tumors is
unknown, it is predicted to be a miRNA binding site of
miR-20a-3p and miR-5001-3p by target prediction pro-
grams including MirSNP and PolymiRTS, and was shown
previously to be impacted by miRNA targeting [16]. We
hypothesize that this may be more complex, with this re-
gion potentially being a landing dock for other RNA bind-
ing proteins, and is work that is ongoing but outside of
the scope of this proposal.
Diminished expression of BRCA1 has previously been
shown to increase the growth rate of benign and malig-
nant breast tissue [38,39]. In another study, loss of nuclear
BRCA1 expression (using IHC) was significantly associ-
ated with high histological grade (p < 0.025) (p < 0.05)
[40]. Both of these findings could help explain the associ-
ation of the BRCA1-3’UTR-variant with tumor progres-
sion and aggressive phenotype. Interestingly, low BRCA1
mRNA expression identified in sporadic breast cancer
specimens has been associated with development of dis-
tant metastasis (p = 0.019) and a shorter disease free inter-
val (p = 0.015) [41]. Additionally, Japanese women whose
tumors stained negative for BRCA1 expression had worse
disease free survival than similar patients whose tumors
were positive for BRCA1 staining [42]. Overall, these find-
ings are in agreement with our findings regarding the
BRCA1-3’UTR-variant, that reduced BRCA1 expression in
the absence of germ-line protein coding sequence variants
may be associated with aggressive tumor biology.
Although the BRCA1-3’UTR-variant has now been
shown to predict a significant increased risk of breast
cancer risk in three independent well-characterized co-
horts, it is notable that this variant has not been reported
from GWAS analyses. We hypothesize that this may be
partly due to the association of the BRCA1-3’UTR-variantwith advanced disease presentation, as patients with Stage
IV cancer are generally underrepresented in cohorts that
are not comprehensive sequential patient collections, such
as the one used in this study, as well as in the Pelletier
triple negative cohort study [17]. Another possibility is
that because this variant, similar to other identified 3’UTR
variants, is altered by “context”, in this case estrogen,
which will be altered by body habitus as well as the soci-
etal acceptance of hormone replacement therapy, it would
make it more likely to be missed in mixed populations
such as those used in GWAS studies. For this new class of
mutation, 3’UTR variants, the homogeneity and appropri-
ate characterization of the study sample is likely to be
much more important than simple sample size.
Our findings suggest a hypothesis where in women
with the BRCA1-3’UTR-variant, if progressing to an es-
trogen independent phenotype, their BRCA1 becomes
even less functional, possibly allowing more DNA dam-
age, and perhaps selection for a more aggressive breast
cancer genotype. These findings could also indicate that
the BRCA1-3’UTR-variant becomes the greatest risk for
cancer development at the time of estrogen withdrawal,
or menopause. While the steps required to lead to breast
tumorigenesis in these patients will require studies with
in vitro and in vivo models, this work represents a sig-
nificant step forward in generating hypotheses about this
variant, as well as understanding the role of this variant,
and other such variants, in cancer biology.
Conclusion
Here we show for the first time that the BRCA1-3’UTR-
variant predicts Stage IV disease, likely due to aggressive
tumor biology. The discovery of a meaningful clinical as-
sociation of the BRCA1-3’UTR-variant in breast cancer
further highlights the importance of studying such vari-
ants in appropriate cohorts to better understand their
clinical potential.
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